NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
Sellas Life Sciences Group
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Zhejiang Cancer Hospital
M.D. Anderson Cancer Center
University Hospital Tuebingen
Shanghai Jiao Tong University School of Medicine
Millennium Pharmaceuticals, Inc.